1423 related articles for article (PubMed ID: 29258605)
1. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
2. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
3. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
[TBL] [Abstract][Full Text] [Related]
4. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
7. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-124-3p.1 promotes cell proliferation through Axin1-dependent Wnt signaling pathway and predicts a poor prognosis of triple-negative breast cancer.
Yang W; Cui G; Ding M; Yang M; Dai D
J Clin Lab Anal; 2020 Jul; 34(7):e23266. PubMed ID: 32125723
[TBL] [Abstract][Full Text] [Related]
9. MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2.
Chen H; Pan H; Qian Y; Zhou W; Liu X
Mol Cancer; 2018 Jan; 17(1):4. PubMed ID: 29310680
[TBL] [Abstract][Full Text] [Related]
10. Serum miR-542-3p as a prognostic biomarker in osteosarcoma.
Li Q; Song S; Ni G; Li Y; Wang X
Cancer Biomark; 2018 Feb; 21(3):521-526. PubMed ID: 29103020
[TBL] [Abstract][Full Text] [Related]
11. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
Turkistani S; Sugita BM; Fadda P; Marchi R; Afsari A; Naab T; Apprey V; Copeland RL; Campbell MC; Cavalli LR; Kanaan Y
BMC Cancer; 2021 Jul; 21(1):861. PubMed ID: 34315420
[TBL] [Abstract][Full Text] [Related]
12. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
Shen H; Yan W; Yuan J; Wang Z; Wang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma.
Fujiwara T; Uotani K; Yoshida A; Morita T; Nezu Y; Kobayashi E; Yoshida A; Uehara T; Omori T; Sugiu K; Komatsubara T; Takeda K; Kunisada T; Kawamura M; Kawai A; Ochiya T; Ozaki T
Oncotarget; 2017 May; 8(20):33375-33392. PubMed ID: 28380419
[TBL] [Abstract][Full Text] [Related]
14. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
[TBL] [Abstract][Full Text] [Related]
15. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
[TBL] [Abstract][Full Text] [Related]
16. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer.
Shin VY; Siu JM; Cheuk I; Ng EK; Kwong A
Br J Cancer; 2015 May; 112(11):1751-9. PubMed ID: 25906045
[TBL] [Abstract][Full Text] [Related]
17. [Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer].
Ma T; Zhang J; Wu J; Tang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 May; 39(5):488-95. PubMed ID: 24921394
[TBL] [Abstract][Full Text] [Related]
18. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
19. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
[TBL] [Abstract][Full Text] [Related]
20. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
